2324 Federal Register / Vol. 77, No. 10 / Tuesday, January 17, 2012 / Notices 

Dated: January 6, 2012. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2012–679 Filed 1–13–12; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a), of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on September 6, 2011 

Cedarburg Pharmaceuticals, Inc., 870 

Badger Circle, Grafton, Wisconsin 

53024, made application by renewal to 

the Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of the following basic 

classes of controlled substances: 

Drug Schedule 

4–Anilino-N-phenethyl-4-piperidine (8333).II 

Fentanyl (9801) ............................ II 

The company plans to manufacture 

the listed controlled substances in bulk 

for distribution to its customers. 

Regarding the drug code (8333), the 

company plans to use this controlled 

substance to manufacture another 

controlled substance. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than March 19, 2012. 

Dated: January 6, 2012. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2012–656 Filed 1–13–12; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a), Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on September 12, 

2011, Johnson Matthey, Inc., 

Pharmaceuticals Materials, 900 River 

Road, Conshohocken, Pennsylvania 

19428, made application by renewal to 

the Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of the following basic 

classes of controlled substances: 

Drug Schedule 

Gamma Hydroxybutyric Acid 

(2010) ................................ I 

Amphetamine (1100) ............ II 

Methylphenidate (1724) ........ II 

Codeine (9050) ..................... II 

Oxycodone (9143) ................ II 

Hydrocodone (9193) ............. II 

Morphine (9300) ................... II 

Thebaine (9333) ................... II 

The company plans to manufacture 

the listed controlled substances in bulk 

for sale in bulk to its customers. The 

Thebaine (9333) will also be used to 

manufacture other controlled substances 

in bulk which will also be for sale in 

bulk to its customers. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than March 19, 2012. 

Dated: January 6, 2012. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2012–653 Filed 1–13–12; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated August 9, 2011, and 

published in the Federal Register on 

August 18, 2011, 76 FR 51401, Austin 

Pharma LLC., 811 Paloma Drive, Suite 

C, Round Rock, Texas 78665–2402, 

made application by renewal to the 

Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of the following basic 

classes of controlled substances: 

Drug Schedule 

Marihuana (7360) ................. I 

Tetrahydrocannabinols 

(7370) ................................ I 

The company plans to manufacture 

bulk active pharmaceutical ingredients 

(APIs) for distribution to its customers. 

In reference to drug code 7360 

(Marihuana), the company plans to bulk 

manufacture cannabidiol as a synthetic 

intermediate. This controlled substance 

will be further synthesized to bulk 

manufacture a synthetic THC (7370). No 

other activity for this drug code is 

authorized for this registration. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Austin Pharma LLC. to manufacture the 

listed basic classes of controlled 

substances is consistent with the public 

interest at this time. DEA has 

investigated Austin Pharma LLC. to 

ensure that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823(a), 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: January 6, 2012. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2012–663 Filed 1–13–12; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated August 10, 2011, and 

published in the Federal Register on 

August 18, 2011, 76 FR 51401, AMRI 

Rensselaer, Inc., 33 Riverside Avenue, 

Rensselaer, New York 12144, made 

application by renewal to the Drug 


srobinson on DSK4SPTVN1PROD with NOTICES